Central role for GSK3β in the pathogenesis of arrhythmogenic cardiomyopathy

JCI Insight

Volumn 1, Issue 5, 2016, Pages

  Chelko, Stephen P ^a   Asimaki, Angeliki ^b   Andersen, Peter ^a   Bedja, Djahida ^a,c   Amat Alarcon, Nuria ^a   DeMazumder, Deeptankar ^a   Jasti, Ravirasmi ^a   MacRae, Calum A ^b   Leber, Remo ^d   Kleber, Andre G ^b   Saffitz, Jeffrey E ^b   Judge, Daniel P ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MACQUARIE UNIVERSITY   (Australia)

^d Schiller AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85134997316     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.85923     Document Type: Article

References (39)

1. Sen-Chowdhry S, McKenna WJ. Sudden death from genetic and acquired cardiomyopathies. Circulation. 2012;125(12):1563–1576.
2. Garcia-Gras E, et al. Suppression of canonical wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J Clin Invest. 2006;116(7):2012–2021.
3. Asimaki A, et al. Identification of a new modulator of the intercalated disc in a zebrafish model of arrhythmogenic cardiomyopathy. Sci Transl Med. 2014;6(240):240ra74.
4. Eldar-Finkelman H, Martinez A. GSK-3 inhibitors: Preclinical and clinical focus on CNS. Front Mol Neurosci. 2011;4:32.
5. Coghlan MP, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol. 2000;7(10):793–803.
6. Lal H, Ahmad F, Woodgett J, Force T. The GSK-3 family as therapeutic target for myocardial diseases. Circ Res. 2015;116(1):138–149.
7. Hirotani S, et al. Inhibition of glycogen synthase kinase 3beta during heart failure is protective. Circ Res. 2007;101(11):1164–1174.
8. Woulfe KC, et al. Glycogen synthase kinase-3beta regulates post-myocardial infarction remodeling and stress-induced cardiomyocyte proliferation in vivo. Circ Res. 2010;106(10):1635–1645.
9. Miura T, Tanno M. Mitochondria and GSK-3β in cardioprotection against ischemia/reperfusion injury. Cardiovasc Drugs Ther. 2010;24(3):255–263.
10. Matsuda T, et al. Distinct roles of GSK-3α and GSK-3β phosphorylation in the heart under pressure overload. Proc Natl Acad Sci U S A. 2008;105(52):20900–20905.
11. Awad MM, et al. DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy. Am J Hum Genet. 2006;79(1):136–142.
12. Kirchhof P, et al. Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation. 2006;114(17):1799–1806.
13. Asimaki A, et al. A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med. 2009;360(11):1075–1084.
14. Ai Z, Fischer A, Spray DC, Brown AM, Fishman GI. Wnt-1 regulation of connexin43 in cardiac myocytes. J Clin Invest. 2000;105(2):161–171.
15. Li VS, et al. Wnt signaling through inhibition of β-catenin degradation in an intact Axin1 complex. Cell. 2012;149(6):1245–1256.
16. Richardson P, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996;93(5):841–842.
17. Asimaki A, et al. Altered desmosomal proteins in granulomatous myocarditis and potential pathogenic links to arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2011;4(5):743–752.
18. James CA, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/Cardiomyopathy–Associated desmosomal mutation carriers. J Am Coll Cardiol. 2013;62(14):1290–1297.
19. Sawant AC, et al. Exercise has a disproportionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients without desmosomal mutations. J Am Heart Assoc. 2014;3(6):e001471.
20. Lal H, et al. Cardiac fibroblast glycogen synthase kinase-3β regulates ventricular remodeling and dysfunction in ischemic heart. Circulation. 2014;130(5):419–430.
21. McManus EJ, et al. Role that phosphorylation of GSK3 plays in insulin and wnt signalling defined by knockin analysis. EMBO J. 2005;24(8):1571–1583.
22. Gillers BS, et al. Canonical wnt signaling regulates atrioventricular junction programming and electrophysiological properties. Circ Res. 2015;116(3):398–406.
23. Eshkind L, Tian Q, Schmidt A, Franke WW, Windoffer R, Leube RE. Loss of desmoglein 2 suggests essential functions for early embryonic development and proliferation of embryonal stem cells. Eur J Cell Biol. 2002;81(11):592–598.
24. Krusche CA, et al. Desmoglein 2 mutant mice develop cardiac fibrosis and dilation. Basic Res Cardiol. 2011;106(4):617–633.
25. Lombardi R, da Graca Cabreira-Hansen M, Bell A, Fromm RR, Willerson JT, Marian AJ. Nuclear plakoglobin is essential for differentiation of cardiac progenitor cells to adipocytes in arrhythmogenic right ventricular cardiomyopathy. Circ Res. 2011;109(12):1342–1353.
26. Zhang Z, et al. Normalization of naxos plakoglobin levels restores cardiac function in mice. J Clin Invest. 2015;125(4):1708–1712.
27. El-Haou S, et al. Kv4 potassium channels form a tripartite complex with the anchoring protein SAP97 and CaMKII in cardiac myocytes. Circ Res. 2009;104(6):758–769.
28. Petitprez S, et al. SAP97 and dystrophin macromolecular complexes determine two pools of cardiac sodium channels Nav1.5 in cardiomyocytes. Circ Res. 2011;108(3):294–304.
29. Milstein ML, et al. Dynamic reciprocity of sodium and potassium channel expression in a macromolecular complex controls cardiac excitability and arrhythmia. Proc Natl Acad Sci U S A. 2012;109(31):E2134–E2143.
30. Gillet L, et al. Cardiac-specific ablation of synapse-associated protein SAP97 in mice decreases potassium currents but not sodium current. Heart Rhythm. 2015;12(1):181–192.
31. Hariharan V, et al. Arrhythmogenic right ventricular cardiomyopathy mutations alter shear response without changes in cell-cell adhesion. Cardiovasc Res. 2014;104(2):280–289.
32. Swope D, Cheng L, Gao E, Li J, Radice GL. Loss of cadherin-binding proteins beta-catenin and plakoglobin in the heart leads to gap junction remodeling and arrhythmogenesis. Mol Cell Biol. 2012;32(6):1056–1067.
33. Sato PY, et al. Interactions between ankyrin-G, plakophilin-2, and Connexin43 at the cardiac intercalated disc. Circ Res. 2011;109(2):193–201.
34. Fabritz L, et al. Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice. J Am Coll Cardiol. 2011;57(6):740–750.
35. Boukens BJ, Rivaud MR, Rentschler S, Coronel R. Misinterpretation of the mouse ECG: ‘musing the waves of mus musculus’. J Physiol (Lond). 2014;592(21):4613–4626.
36. Andrassy M, et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation. 2008;117(25):3216–3226.
37. Beauchamp P, et al. Electrical coupling and propagation in engineered ventricular myocardium with heterogeneous expression of connexin43. Circ Res. 2012;110(11):1445–1453.
38. Geisse NA, Sheehy SP, Parker KK. Control of myocyte remodeling in vitro with engineered substrates. In Vitro Cell Dev Biol Anim. 2009;45(7):343–350.
39. Singhvi R, et al. Engineering cell shape and function. Science. 1994;264(5159):696–698.